- Home
- AVTX vs HLVX Comparison
AVTX vs HLVX Comparison
Compare AVTX & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- HLVX
- Stock Information
- Founded
- AVTX 2011
- HLVX 2020
- Country
- AVTX United States
- HLVX United States
- Employees
- AVTX N/A
- HLVX N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- HLVX Health Care
- Exchange
- AVTX Nasdaq
- HLVX Nasdaq
- Market Cap
- AVTX 88.4M
- HLVX 92.9M
- IPO Year
- AVTX 2015
- HLVX 2022
- Fundamental
- Price
- AVTX $7.73
- HLVX $1.83
- Analyst Decision
- AVTX Strong Buy
- HLVX Hold
- Analyst Count
- AVTX 4
- HLVX 5
- Target Price
- AVTX $33.00
- HLVX $2.33
- AVG Volume (30 Days)
- AVTX 54.4K
- HLVX 187.3K
- Earning Date
- AVTX 03-28-2025
- HLVX 03-19-2025
- Dividend Yield
- AVTX N/A
- HLVX N/A
- EPS Growth
- AVTX N/A
- HLVX N/A
- EPS
- AVTX N/A
- HLVX N/A
- Revenue
- AVTX $820,000.00
- HLVX N/A
- Revenue This Year
- AVTX N/A
- HLVX N/A
- Revenue Next Year
- AVTX N/A
- HLVX N/A
- P/E Ratio
- AVTX N/A
- HLVX N/A
- Revenue Growth
- AVTX N/A
- HLVX N/A
- 52 Week Low
- AVTX $4.18
- HLVX $1.55
- 52 Week High
- AVTX $34.46
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- AVTX 47.38
- HLVX 42.62
- Support Level
- AVTX $7.42
- HLVX $1.67
- Resistance Level
- AVTX $8.50
- HLVX $1.97
- Average True Range (ATR)
- AVTX 0.69
- HLVX 0.08
- MACD
- AVTX 0.06
- HLVX -0.02
- Stochastic Oscillator
- AVTX 38.90
- HLVX 43.72
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.